KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Current Assets (2016 - 2025)

Astrazeneca (AZN) has 3 years of Current Assets data on record, last reported at $28.7 billion in Q4 2025.

  • For Q4 2025, Current Assets rose 11.21% year-over-year to $28.7 billion; the TTM value through Dec 2025 reached $28.7 billion, up 11.21%, while the annual FY2025 figure was $28.7 billion, 11.21% up from the prior year.
  • Current Assets reached $28.7 billion in Q4 2025 per AZN's latest filing, up from $25.8 billion in the prior quarter.
  • Across five years, Current Assets topped out at $28.7 billion in Q4 2025 and bottomed at $25.1 billion in Q4 2023.
  • Average Current Assets over 3 years is $26.5 billion, with a median of $25.8 billion recorded in 2024.
  • Peak YoY movement for Current Assets: increased 3.09% in 2024, then grew 11.21% in 2025.
  • A 3-year view of Current Assets shows it stood at $25.1 billion in 2023, then grew by 3.09% to $25.8 billion in 2024, then grew by 11.21% to $28.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $28.7 billion in Q4 2025, $25.8 billion in Q4 2024, and $25.1 billion in Q4 2023.